Τομέας Κλινικοεργαστηριακός

22. Z. Papoutsi, E Kassi, Halabalaki M, S. Mitakou, P. Moutsatsou. Evaluation of estrogenic/antiestrogenic activity of Onobrychis
ebenoides extract - Interaction with estrogen receptor subtypes ERalpha andERbeta. Toxicol In Vitro. 2007 Apr;
21(3):364-70.
23. Z.Papoutsi, E.Kassi, S.Mitakou, N.Aligiannis, A.Tsiapara, G.P.Chrousos, P.Moutsatsou . Acteoside and Martynoside exhibit
estrogenic/antiestrogenic properties. J Steroid Biochem Mol Biol. 2006 Jan; 98(1):63-71
24. Z.Papoutsi, E.Kassi, A.Tsiapara, P.Moutsatsou. Evaluation of estrogenic/ antiestrogenic activity of ellagic acid via the estrogen
receptor subtypes ERá and ERâ. Journal of Agricultural and Food Chemistry 2005 Oct 5; 53(20):7715-20
25. Kassi E , Papoutsi Z , Fokialakis N , Mitakou S , Moutsatsou P. Greek plant extracts exhibit Selective Estrogen Receptor
Modulator (SERM) -like properties. Journal of Agricultural and Food Chemistry, 2004 Nov 17; 52(23):6956-61
26. E.Kassi, P.G Vlachoyiannopoulos, A.Kominakis, H.Kiarris, H.M.Moutsopoulos, P.Moutsatsou Estrogen receptor alpha gene
polymorphism and systemic lupus erythematosus : a possible risk? Lupus 2005; 14(5):391-8.
27. L. Fountas, M. Anapliotou, C.E Sekeris, E Kassi, P. Moutsatsou. Estrogen receptor alpha gene analysis in osteoporosis and
familial osteoporosis. Osteoporosis Int, 2004 Dec; 15(12):948-56.
28. Dalamaga M, Karmaniolas K, Chavelas C, Liatis S, Matekovits H, Migdalis I. Coexistence of primary refractory anemia with
ringed sideroblasts (RARS) and T-cell lymphoblastic non-Hodgkin lymphoma. Acta Haematologica 2004; 111(3): 171-172.
Impact factor: 0.796.
29. Dalamaga M, Karmaniolas K, Chavelas C, Liatis S, Ioannidis P, Matekovits E-A, Migdalis I. Generalised infection associated
with ECHO virus. European Journal of Internal Medicine 2004; 15: 68.
30. Dalamaga M, Karmaniolas K, Chavelas C, Liatis S, Matekovits H, Migdalis I. Pseudomonas fluorescens cutaneous abscess
and recurrent bacteremia following a dog bitE International Journal of Dermatology 2005; 44(4): 347-349. Impact factor:
0.998.
31. Dalamaga M, Karmaniolas K, Chavelas C, Liatis S, Matekovits H, Migdalis I. Pseudomonas luteola cutaneous abscess and
bacteremia in a previously healthy man. Scandinavian Journal of Infectious Diseases 2004; 36(6-7): 495-497. Impact factor:
1.108.
32. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Delia MA, Papadiamantis Y, Markopoulos C, Spanos E,
Chrousos G, Trichopoulos D. Adiponectin and Breast Cancer Risk. Journal of Clinical Endocrinology and Metabolism
2004; 89(3): 1102-1107. Impact factor: 5.799
33. Petridou E, Kouri N, Vadala H, Dalamaga M, Sege R. Frequency and nature of recorded childhood immunization related
errors in GreecE Journal of Toxicology-Clinical Toxicology 2004; 42(3): 273-276. Impact factor: 1.369
34. *Moustaki M, Pitsos N, Dalamaga M, Dessypris N, Petridou E Home and leisure activities and childhood knee injuries.
Injury 2005; 36 (5): 644-650. Impact factor: 1.067.
35. *Dalamaga M, Chavelas C, Kostoula A, Matekovits E-A, Liatis S, Karmaniolas K, Migdalis I. Leptospirosis presenting as
acute pancreatitis and cholecystitis Journal of Medicine (J Med) 2004; 35 (1-6):181-185. Impact factor: 0.114
36. *Dalamaga M, Karmaniolas K, Kontos F, Migdalis I, Dionyssiou-Asteriou A. Clinical study on the serum carcinoembryonic
antigen, CA 19-9, CA 50 and á-fetoprotein levels in patients with myelodysplastic syndromes Leukemia and Lymphoma
2006; 47(9): 1782-1787. Impact factor: 1.559
37. *Dalamaga M, Karmaniolas K, Pantelaki M, Daskalopoulou K, Kavatha D, Migdalis I. Spontaneous peritonitis caused by
Leminorella grimontii. Diagn Microbiol Infect Dis 2006; 56:83-85. Impact factor: 2.2.
38. *Karmaniolas K, Liatis S, Dalamaga M, Mourouti G, Digeni A, Migdalis I. A case of ovarian sarcoidosis mimicking malignancy.
Eur J Gynaecol Oncol 2005; 26 (2): 231-232. Impact factor: 0.6.
39. *Papadavid E, Gazi S, Dalamaga M, Stavrianeas N, Ntelis V. Palmoplantar and scalp psoriasis occurring during anti-tumour
necrosis factor-á: a case series of four patients and guidelines for management. Journal of the European Academy of Dermatology
and Venereology 2008; 22: 380-2. Impact factor: 1.638.
40. *Dalamaga M, Karmaniolas K, Matekovits A, Migdalis I, Papadavid E Cutaneous manifestations in relation to immunologic
parameters in a cohort of primary myelodysplastic syndrome patients. Journal of the European Academy of Dermatology
and Venereology 2008; 22: 543-8. Impact factor: 1.638.
41. *Dalamaga M, Nikolaidou A, Karmaniolas K, His A, Chamberland J, Dionyssiou-Asteriou A, Mantzoros C. Circulating adiponectin
and leptin in relation to myelodysplastic syndrome: a case-control study. Oncology 2007; 73 (1-2): 26-32.
Impact factor: 3.2
42. *Dalamaga M, Karmaniolas K, Arsenis G, Pantelaki M, Daskalopoulou K, Papadavid E, Migdalis I. Cedecae lapagei bacteremia
following cement-related chemical burn injury. Burns (in press). Impact factor: 1.3.
43. *Dalamaga M, Karmaniolas K, Nikolaidou A, Papadavid E Hypocalcemia, hypomagnesemia and hypokalemia following hydrofluoric
acid chemical injury. Journal of Burn Care & Research 2008; 29: 541-543. Impact factor: 1.037.
44. *Dalamaga M, Lekka A, Karmaniolas K, Stathopoulou E, Dionyssiou-Asteriou A. Is thyroid autoimmunity a risk factor for
developing primary myelodysplastic syndrome? Cancer Causes and Control 2008; 19: 371-8. Impact factor: 2.92.
45. *Papadavid E, Psyrri A, Pectasides D, Katoulis A, Belamoti E, Dalamaga M, Stavrianeas N. Melanoma in psoriatic patient.
How to managE Dermatology 2008; 216: 277-278. Impact factor: 1.854.
2128 ¸êèåóç ÅóùôåñéêÞò Áîéïëüãçóçò (Ðñüôõðï ó÷Þìá)